News >

Expert Summarizes Strides in Relapsed Myeloma, Says More to Come

Caroline Seymour
Published: Tuesday, May 08, 2018

Peter Voorhees, MD

Peter Voorhees, MD
Triplet regimens have become the preeminent means of treatment for patients with relapsed multiple myeloma, and Peter Voorhees, MD, explained that the results of the phase III OPTIMISMM trial of bortezomib (Velcade) and dexamethasone with or without pomalidomide (Pomalyst) may give physicians yet another 3-drug regimen to use in earlier lines of therapy.

on Hematologic Malignancies, Voorhees discussed treatments for patients with early relapsed multiple myeloma and previewed future research efforts.

OncLive: Please provide an overview of your presentation. 

Voorhees: I spoke about treatment options for patients with early relapsed multiple myeloma, and by early relapse I mean patients in first- or second- relapse who require second- and third- line therapy. There are more available options for patients with relapsed multiple myeloma than there have ever been.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x